Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Best Low-Interest Personal Loans 0.50% discount on regular rates with AutoPay 6.99% to 25.49% (with AutoPay discount, rates vary by loan purpose) $5,000 to $100,000 660 LightStream offers some of ...